

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
NeuroNova AB (Company Registration No. 556554-8293)	11/22/2006

RECEIVING PARTY DATA

Name:	NeuroNova AB (Company Registration No. 556703-0118)
Street Address:	Fiskartorpsvagen 15A-D, SE 114 33
City:	Stockholm
State/Country:	SWEDEN

PROPERTY NUMBERS Total: 15

Property Type	Number
Patent Number:	6969702
Application Number:	10246091
Application Number:	10291290
Application Number:	10429062
Application Number:	10434943
Application Number:	10641925
Application Number:	10850055
Application Number:	11288495
Application Number:	10993667
Application Number:	10718071
Application Number:	10938491
Application Number:	60737711
Application Number:	60814338
Application Number:	60752210
Application Number:	60800732

CH \$600.00 6969702

PATENT

500186236

REEL: 018563 FRAME: 0365

CORRESPONDENCE DATA

Fax Number: (212)983-3115

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-935-3000

Email: esinn@mintz.com

Correspondent Name: Eric Sinn

Address Line 1: 666 Third Avenue, 24th Floor

Address Line 4: New York, NEW YORK 10017

ATTORNEY DOCKET NUMBER:

21882-500

NAME OF SUBMITTER:

Eric Sinn

Total Attachments: 5

source=21882-500_Transmittal Letter#page1.tif

source=21882-500_Recordation Cover Sheet#page1.tif

source=21882-500_Assignment_3 pages total#page1.tif

source=21882-500_Assignment_3 pages total#page2.tif

source=21882-500_Assignment_3 pages total#page3.tif

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assignor: NeuroNova AB, Company Registration Number: 556554-8293
Assignee: NeuroNova AB, Company Registration Number: 556703-0118
First Serial Number: 10/246,091
Filing Date: September 18, 2002
Customer No.: 35437

MAIL STOP ASSIGNMENT RECORDATION SERVICES

Director of the United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith for filing in the present application are the following documents:

1. Recordation Cover Sheet (1 page); and
2. Executed Assignment and Schedule A—one counterpart (3 pages total)

The Commissioner is authorized to charge \$600.00 and any deficiencies to Deposit Account No. **50-0311**, Reference No. **21882-500**, Customer Number: **35437**.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000, New York, New York.

Respectfully submitted,



Date: November 30, 2006

Eric Sinn, Reg. No. 40,177
Attorney/Agent for Applicants
c/o MINTZ, LEVIN, *et al.*
666 Third Avenue-24th Floor
New York, New York 10017
Telephone: (212) 935-3000
Telefax: (212) 983-3115

Date of Deposit: November 30, 2006

Attorney Docket No. 21882-500

RECORDATION FORM COVER SHEET
PATENTS ONLY

FORM PTO-1595

(Rev. 6-93)

OMB No. 0651-0011 (exp. 4/94)

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

NeuroNova AB
Company Registration Number: 556554-8293
Fiskartorpsvagen 15A-D
Suite 114 33
STOCKHOLM, SWEDEN

2. Name and address of receiving party(ies)

NeuroNova AB
Company Registration Number: 556703-0118
Fiskartorpsvagen 15A-D
SE 114 33
STOCKHOLM, SWEDENAdditional name(s) of conveying party(ies) attached? ☐ Yes ☒ NoAdditional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other

Execution Date: November 22, 2006

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is _____

A. Patent Application No(s):

10/246,091, Filed September 18, 2002
(Additional Patent Application Numbers continued
on Schedule A attached hereto.)

B. Patent No(s):

Please See Schedule A attached hereto

Additional numbers attached? ☒ Yes ☐ No5. Name and address of party to whom correspondence
Concerning document should be mailed:Name: Eric Sinn, Esq.
Address: MINTZ, LEVIN, COHN, FERRIS
GLOVSKY and POPEO, P.C.
666 Third Avenue, 24th Floor
New York, New York 10017
Telephone: (212) 935-3000
Telefax: (212) 983-31156. Total number of applications and patents involved: [15]

7. Total fee (37 CFR 3.41) \$600.00

- ☐ Enclosed
☒ The Commissioner is authorized to charge Deposit Account No: 50-0311,
Reference No. 21882-500 for any deficiencies.

DO NOT USE THIS SPACE

9. Statement and signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Eric Sinn, Reg. No. 40,177



November 30, 2006

Name of Person Signing

Signature

Date

Total number of pages including cover sheet, attachments, and document: (5)

Mail documents to be recorded with required cover sheet information to:

MAIL STOP ASSIGNMENT RECORDATION SERVICES
Director of the United States Patent and Trademark OfficeP. O. Box 1450
Alexandria, VA 22313-1450

ASSIGNMENT

NeuroNova AB, Company Registration Number 556554-8293, a corporation organized under the laws of Sweden, having principal offices at Fiskartorpsvägen 15 A-D, Suite 114 33 Stockholm, Sweden (the "ASSIGNOR"), for good and valuable consideration, the receipt of which is hereby acknowledged, hereby assigns, sells and transfers to NeuroNova AB, Company Registration Number 556703-0118, a corporation organized under the laws of Sweden, having principal offices at Fiskartorpsvägen 15 A-D, SE 114 33 Stockholm, Sweden, and its successors, assigns and legal representatives, all hereinafter referred to as the "ASSIGNEE": (1) the entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the patents and applications for patents as listed in Schedule A, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in the name of NeuroNova AB, Company Registration Number 556703-0118 as the ASSIGNEE, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patents which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

ASSIGNOR hereby authorizes and requests the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR, had this assignment, sale and transfer not been made.

ASSIGNOR agrees, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

ASSIGNOR further agrees at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

Express Mail Label No.: EV886686735US

Date of Deposit: November 30, 2006


Attorney Docket No.: 21882-500

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

ASSIGNOR further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

For NeuroNova AB, Company Registration Number 556554-8293.

Date 22/11/06

Signature of: 

Title: CEO


Witness


Nov 22, 2006
Date


Witness

Nov 22, 2006
Date

For NeuroNova AB, Company Registration Number 556703-0118:

Date 22/11/06

Signature of: 

Title: PROJECT & PATENT MANAGER


Witness

Nov 22, 2006
Date


Witness

Nov 22, 2006
Date

~~Express Mail Label No.: EV886686735US~~

Date of Deposit: November 30, 2006

Attorney Docket No.: 21882-500

SCHEDULE A

U.S. Patent Application Serial No. / U.S. Patent No.	Attorney Docket Number
1. 10/246,091, Filed September 18, 2002 Entitled: "Treatment of Central Nervous System Disorders"	21882-504 UTIL
2. 10/291,290, Filed November 8, 2002 Entitled: "Method of Proliferation in Neurogenic Regions"	21882-505 UTIL
3. 10/429,062, Filed May 2, 2003 Entitled: "The Functional Role and Potential Therapeutic Use of PCAP and VIP and Their Receptors ADCYAP1R1 VIPR1 and VIPR2 in Relation to Adult Neural Stem or Progenitor Cells"	21882-509 UTIL
4. 10/434,943, Filed May 8, 2003 Entitled: "Modulation of Neural Stem Cell and Neural Progenitor Cells"	21882-510 UTIL
5. 10/641,925, Filed August 15, 2003 Entitled: "Therapeutic Use of Selective LXR Modulators"	21882-512 UTIL
6. 10/850,055, Filed May 19, 2004 / 6,969,702, Issued November 29, 2005 Entitled: "Compounds and Methods for Increasing Neurogenesis"	21882-517 CIP
7. 11/288,495, Filed November 28, 2005 Entitled: "Compounds and Methods for Increasing Neurogenesis"	21882-517 CIP DIV
8. 10/993,667, Filed November 19, 2004 Entitled: "Compounds and Methods for Increasing Neurogenesis"	21882-517 CIP2
9. 10/718,071, Filed November 20, 2003 Entitled: "Compounds and Methods for Increasing Neurogenesis"	21882-517 UTIL
10. 10/938,491, Filed September 10, 2004 Entitled: "Treatment of Disease or Injury of the Nervous System with FTY720"	21882-527 UTIL
11. 60/737,711, Filed November 16, 2005 Entitled: "Identification of Gene Sequences and Gene Products with Specific Functions in Adult Neural Stem Cell Biology"	21882-528 PRO3
12. 60/814,338, Filed June 15, 2006 Entitled: "Method for the Treatment of CNS Cancer"	21882-531 PRO2
13. 60/752,210, Filed December 19, 2005 Entitled: "Treatment of Disease or Injury of the Nervous System Using Antagonists for the Melanocortin 4 Receptor"	21882-532 PRO
14. 60/800,732, Filed May 15, 2006 Entitled: "Compositions and Methods for Treatment of Neurological Disease Using VMAT2"	21882-533 PRO1